Longitudinal Observational Study of Severe Asthma

NCT ID: NCT01780142

Last Updated: 2026-01-23

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 171 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-03-01

Brief Summary

Background:

• Asthma is a lung condition that causes difficulty breathing and decreased lung function. Some people with asthma have more severe disease symptoms. They may be less responsive to standard treatments such as steroids. Researchers want to compare severe asthmatics with mild or moderate asthmatics or people without asthma over a long period. This information may help identify new treatments for people whose asthma is not well controlled by standard medications.

Objectives:

• To compare severe asthmatics with mild or moderate asthmatics, and healthy volunteers, to study the progression and outcomes of the disease.

Eligibility:

• Individuals at least 18 years of age who have been diagnosed with asthma for at least 1 year.
• Healthy volunteers at least 18 years of age.

Design:

• This study will involve an initial visit to the NIH Clinical Center for all participants. Selected participants may be asked to return for repeat visits over a number of years. The test results from participants with asthma will be compared with those from the healthy volunteers.
• All participants will be screened with a physical exam and medical history.
• Participants may (but will not necessarily) have the following tests at each visit:
• Complete medical history and physical exam
• Blood, urine, sputum, and nasal cell samples
• Breath tests and heart and lung function tests
• Six-minute walk test to measure ability to exercise
• Imaging studies such as chest x-rays, bone density scans, and sinus scans
• Allergy skin testing
• Vocal cord exam
• Overnight sleep study
• Participants may remain on the study for as long as they are willing to participate and do not develop health problems that will interfere with the study.

Detailed Description

Asthma is a common disease and a significant public health problem, affecting one in every 10 individuals, nearly 30 million people in the US alone. About 5-10% of asthmatics have severe disease that is difficult to control with standard therapies. Severe asthmatics are considered to be relatively resistant to corticosteroids, a mainstay of therapy in asthma. Furthermore, chronic corticosteroid therapy often results in side effects that adversely affect outcomes. Thus, more effective treatment options, which are safe, cost-effective and easy to administer, are needed for severe asthmatics.

As our understanding of asthma evolves, it is becoming clearer that there are distinct phenotypes that differ regarding demographic factors such as age, sex and race, but also, perhaps more importantly, with regards to clinical, physiologic and biologic characteristics. This heterogeneity may reflect distinct pathogenic mechanisms that result in airflow obstruction and the clinical presentation of asthma. In turn, a better understanding of the different factors that contribute to disease severity and pathogenesis will be necessary to identify new, personalized treatment and management approaches for severe asthmatics. Our goal is to gain a better understanding of the pathogenic mechanisms that differentiate severe asthma from mild to moderate asthma, including the role of the above-mentioned factors on disease control. In so doing, we hope to discover novel pathways that can be manipulated to achieve our primary aim of developing new therapies for severe asthmatics.

Conditions

Asthma

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

asthmatics

Subjects with confirmed diagnosis of asthma without other lung disease followed for collection of clinical data \& specimens

No interventions assigned to this group

non-asthmatic healthy volunteers

Healthy volunteers in whom asthma has been ruled out and without other lung disease followed for comparison to asthmatics

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Subjects must be over 18 years of age.
• Subjects must have had a diagnosis of asthma, as defined by the American Thoracic Society, for at least one year to enter this study.
• Subjects must have a history of reversible airflow obstruction, as defined by a positive response to inhaled bronchodilators or a positive methacholine bronchoprovocation challenge by ATS criteria. Severe, refractory asthma will be defined by the 2000 ATS workshop consensus criteria. Refractory asthmatics will meet one or both of the major criteria and at least two minor criteria as outlined in the Protocol. This definition is applicable only to patients in whom (1) other conditions have been excluded, (2) exacerbating factors have been optimally treated, and (3) poor adherence does not appear to be a confounding issue. Compliance or medication adherence will be assessed at the initial and subsequent visits by questioning the subjects about their medication use (self-report).
• If asthmatic subjects do not fulfill the criteria for severe asthma, they will be classified as mild to moderate asthmatics.
• Subjects must have the ability to provide informed consent.

• Subjects must be at least 18 years of age without a clinical diagnosis of asthma.
• Subjects must have no evidence of obstructive airway disease, as defined by ATS criteria on spirometry, and a negative methacholine bronchoprovocation challenge.
• Subjects must have the ability to provide informed consent.
• Subjects will be matched to asthmatics by gender and age (+/- 10 years).

Exclusion Criteria

• Any concurrent condition (medical, social or behavioral) that, in the opinion of the research team, would preclude or confound acquisition or interpretation of data or delivery of care.
• Subjects must not be pregnant

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Amisha V Barochia, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Heart, Lung, and Blood Institute (NHLBI)

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

Countries

United States

References

Barochia AV, Gordon EM, Kaler M, Cuento RA, Theard P, Figueroa DM, Yao X, Weir NA, Sampson ML, Stylianou M, Choy DF, Holweg CTJ, Remaley AT, Levine SJ. High density lipoproteins and type 2 inflammatory biomarkers are negatively correlated in atopic asthmatics. J Lipid Res. 2017 Aug;58(8):1713-1721. doi: 10.1194/jlr.P077776. Epub 2017 Jun 27.

Reference Type: BACKGROUND

PMID: 28655726 (View on PubMed)

Barochia AV, Kaler M, Cuento RA, Gordon EM, Weir NA, Sampson M, Fontana JR, MacDonald S, Moss J, Manganiello V, Remaley AT, Levine SJ. Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma. Am J Respir Crit Care Med. 2015 May 1;191(9):990-1000. doi: 10.1164/rccm.201411-1990OC.

Reference Type: BACKGROUND

PMID: 25692941 (View on PubMed)

Related Links

https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-H-0059.html

NIH Clinical Center Detailed Web Page

Other Identifiers

13-H-0059

Identifier Type: -

Identifier Source: secondary_id

130059

Identifier Type: -

Identifier Source: org_study_id